CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

The fact that the European Medicines Agency (EMA) advised against conditional approval adds to the cautious approach. Moreover, Agenus’s ongoing investigator-sponsored trials (ISTs) in the neoadjuvant ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing ...

Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a GMP certificate from the European Medicines Agency for its ...

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

Aarti Industries, Aditya Birla Fashion Retail, Granules India, Hindustan Copper, Manappuram Finance are banned from F&O trading on 13 November 2024.

Indian shares will likely open little changed on Wednesday after a rise in October retail inflation dampened hopes of a rate ...

Global health is likely to be radically altered with Donald Trump in the White House. For starters, the president-elect has ...

Sick people in our country could lose access to essential medicines such as Paracetamol and Metformin (a basic treatment for ...